Bio-Connect
FACS analysis of human peripheral blood lymphocytes using GTX01455-08 CD19 antibody [HIB19] (PE). Solid lone : primary antibody Dashed line : isotype control antibody amount : 0.25 microg (5 microl)
FACS analysis of human peripheral blood lymphocytes using GTX01455-08 CD19 antibody [HIB19] (PE). Solid lone : primary antibody Dashed line : isotype control antibody amount : 0.25 microg (5 microl)
FACS analysis of human peripheral blood lymphocytes using GTX01455-08 CD19 antibody [HIB19] (PE). Solid lone : primary antibody Dashed line : isotype control antibody amount : 0.25 microg (5 microl)

CD19 antibody [HIB19] (PE)

GTX01455-08
GeneTex
ApplicationsFlow Cytometry
Product group Antibodies
TargetCD19
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    CD19 antibody [HIB19] (PE)
  • Delivery Days Customer
    9
  • Application Supplier Note
    FACS: 0.25 microg (5 microl) for 105-108 cells in 100 microl sample per test. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Applications
    Flow Cytometry
  • Certification
    Research Use Only
  • Clonality
    Monoclonal
  • Clone ID
    HIB19
  • Concentration
    0.05 mg/ml
  • Conjugate
    RPE
  • Gene ID930
  • Target name
    CD19
  • Target description
    CD19 molecule
  • Target synonyms
    B4, CVID3, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4, T-cell surface antigen Leu-12, differentiation antigen CD19
  • Host
    Mouse
  • Isotype
    IgG1
  • Protein IDP15391
  • Protein Name
    B-lymphocyte antigen CD19
  • Scientific Description
    Lymphocytes proliferate and differentiate in response to various concentrations of different antigens. The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors. This gene encodes a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation. [provided by RefSeq, Jul 2008]
  • Storage Instruction
    2°C to 8°C
  • UNSPSC
    12352203

References

  • Richards KA, Moritzky S, Shannon I, et al. Recombinant HA-based vaccine outperforms split and subunit vaccines in elicitation of influenza-specific CD4 T cells and CD4 T cell-dependent antibody responses in humans. NPJ Vaccines. 2020,5:77. doi: 10.1038/s41541-020-00227-x
    Read this paper
  • Zhao NQ, Vendrame E, Ferreira AM, et al. Natural killer cell phenotype is altered in HIV-exposed seronegative women. PLoS One. 2020,15(9):e0238347. doi: 10.1371/journal.pone.0238347
    Read this paper
  • Stoszko M, Al-Hatmi AMS, Skriba A, et al. Gliotoxin, identified from a screen of fungal metabolites, disrupts 7SK snRNP, releases P-TEFb, and reverses HIV-1 latency. Sci Adv. 2020,6(33):eaba6617. doi: 10.1126/sciadv.aba6617
    Read this paper
  • Benjelloun F, Quillay H, Cannou C, et al. Activation of Toll-Like Receptors Differentially Modulates Inflammation in the Human Reproductive Tract: Preliminary Findings. Front Immunol. 2020,11:1655. doi: 10.3389/fimmu.2020.01655
    Read this paper
  • Krüger R, Martin E, Dmytrus J, et al. CD70 Deficiency Associated With Chronic Epstein-Barr Virus Infection, Recurrent Airway Infections and Severe Gingivitis in a 24-Year-Old Woman. Front Immunol. 2020,11:1593. doi: 10.3389/fimmu.2020.01593
    Read this paper
  • Bézie S, Freuchet A, Sérazin C, et al. IL-34 Actions on FOXP3(+) Tregs and CD14(+) Monocytes Control Human Graft Rejection. Front Immunol. 2020,11:1496. doi: 10.3389/fimmu.2020.01496
    Read this paper
  • Giron LB, Colomb F, Papasavvas E, et al. Interferon-α alters host glycosylation machinery during treated HIV infection. EBioMedicine. 2020,59:102945. doi: 10.1016/j.ebiom.2020.102945
    Read this paper
  • Salzer B, Schueller CM, Zajc CU, et al. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nat Commun. 2020,11(1):4166. doi: 10.1038/s41467-020-17970-3
    Read this paper
  • Kreye J, Reincke SM, Kornau HC, et al. A SARS-CoV-2 neutralizing antibody protects from lung pathology in a COVID-19 hamster model. bioRxiv. 2020,:pii: 2020.08.15.252320. doi: 10.1101/2020.08.15.252320.
    Read this paper
  • Pierini S, Tanyi JL, Simpkins F, et al. Ovarian granulosa cell tumor characterization identifies FOXL2 as an immunotherapeutic target. JCI Insight. 2020,5(16):pii: 136773. doi: 10.1172/jci.insight.136773.
    Read this paper